BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 20130438)

  • 1. New agents in advanced non-small-cell lung cancer treatment.
    Ricciardi S; de Marinis F
    Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Third-line therapy for advanced non-small-cell lung cancer patients: a feasible therapeutic option?
    Galetta D; Rossi A; Colucci G; Gebbia V
    Oncology; 2009; 77 Suppl 1():113-21. PubMed ID: 20130439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR; Dragnev KH
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic chemotherapy in advanced non-small cell lung cancer: a review of standard treatment paradigms.
    Socinski MA
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4210s-4214s. PubMed ID: 15217960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
    Maione P; Gridelli C; Troiani T; Ciardiello F
    Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triplet chemotherapy combinations with new agents: is there a rationale?
    Bunn PA
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):55-61. PubMed ID: 9728586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporation of paclitaxel and carboplatin in combined-modality therapy for locally advanced non-small cell lung cancer.
    Belani CP
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):44-54. PubMed ID: 10190783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
    Socinski MA; Shea TC
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E; Herbst RS
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined targeted therapies in non-small cell lung cancer: a winner strategy?
    Cascone T; Gridelli C; Ciardiello F
    Curr Opin Oncol; 2007 Mar; 19(2):98-102. PubMed ID: 17272980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential, alternating, and maintenance/consolidation chemotherapy in advanced non-small cell lung cancer: a review of the literature.
    Grossi F; Aita M; Follador A; Defferrari C; Brianti A; Sinaccio G; Belvedere O
    Oncologist; 2007 Apr; 12(4):451-64. PubMed ID: 17470688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Present trends in the treatment of advanced non small-cell lung cancer.
    Parvez T; Allam AR; Iskandrani A; Khan MA
    J Coll Physicians Surg Pak; 2003 Aug; 13(8):483-90. PubMed ID: 12921691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of therapy decision-making process for advanced non-small cell lung cancer.
    Gebbia V; Mancuso G; Lombardi L; Maiello E
    Oncology; 2009; 77 Suppl 1():97-102. PubMed ID: 20130437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.